Cough Medicine May Protect Against Some of Parkinson's Worst Symptoms
The drug, ambroxol, isn't approved for use in the US, Canada, or Australia, but it is commonly found in cough syrups and tablets from Europe.
In a gold-standard phase 2 clinical trial, 22 participants with Parkinson's dementia who received a high daily dose of ambroxol for a year showed no worsening of key neuropsychiatric symptoms.
Meanwhile, 25 patients who received the placebo displayed worsening symptoms, gaining an average of 3.73 points on an established neuropsychiatric score. Patients on ambroxol dropped an average of 2.45 points.
Related:
Both groups shared similar cognitive scores related to memory and language. But those taking ambroxol showed stabilization in symptoms like delusions, hallucinations, anxiety, irritability, apathy, and aberrant motor activity.
Participants on ambroxol also experienced fewer falls.
Though ambroxol was found to be safe, no clinically meaningful improvements in cognition were recorded. Yet there are reasons to remain optimistic.
"Our goal was to change the course of Parkinson's dementia," says neurologist Stephen Pasternak from Western University in Canada.
"This early trial offers hope and provides a strong foundation for larger studies."
In the team's analysis, some participants carrying a high-risk GBA1 gene for Parkinson's showed improved cognitive performance on ambroxol. With a small sample size and no control group to compare outcomes to, the authors caution these results need to be followed up before drawing any conclusions.
That said, high-risk GBA1 gene variants tend to result in lower activity of the enzyme Glucocerebrosidase (GCase), and this, in turn, is linked to more protein clumps in the brain, like Lewy bodies, which are associated with Parkinson's dementia.
Recently, studies have found that ambroxol can significantly increase GCase activity. In the current trial, those taking the drug showed 1.5 times the amount of GCase activity.
No serious adverse effects were reported by those taking ambroxol, although mild to moderate gastrointestinal issues were common and caused a few participants to drop out of the trial.
The findings suggest that some of the more serious symptoms of Parkinson's disease may be managed by ambroxol if taken regularly at high doses.
Because ambroxol can easily cross the blood-brain barrier, some scientists suspect the cough medicine can treat neurodegenerative conditions, like Parkinson's, Amyotrophic lateral sclerosis (ALS), Gaucher disease, neuroinflammation, or spinal cord injury.
Whether that hypothesis proves to be true requires more clinical research. But the recent phase 2 trial on Parkinson's dementia gives scientists good reason to keep digging.
"These findings suggest ambroxol may protect brain function, especially in those genetically at risk," says Pasternak.
"It offers a promising new treatment avenue where few currently exist. If a drug like Ambroxol can help, it could offer real hope and improve lives."
The study was published in JAMA Neurology.
Scientists Finally Uncovered Where Gluten Reactions Start
One Major Feature of Aging Might Not Be Universal After All
Brain's Memory Center Never Stops Making Neurons, Study Confirms
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Cough Medicine May Protect Against Some of Parkinson's Worst Symptoms
An active ingredient in cough medicines since 1979 has shown promise as a treatment for neuropsychiatric symptoms in Parkinson's disease-related dementia. The drug, ambroxol, isn't approved for use in the US, Canada, or Australia, but it is commonly found in cough syrups and tablets from Europe. In a gold-standard phase 2 clinical trial, 22 participants with Parkinson's dementia who received a high daily dose of ambroxol for a year showed no worsening of key neuropsychiatric symptoms. Meanwhile, 25 patients who received the placebo displayed worsening symptoms, gaining an average of 3.73 points on an established neuropsychiatric score. Patients on ambroxol dropped an average of 2.45 points. Related: Both groups shared similar cognitive scores related to memory and language. But those taking ambroxol showed stabilization in symptoms like delusions, hallucinations, anxiety, irritability, apathy, and aberrant motor activity. Participants on ambroxol also experienced fewer falls. Though ambroxol was found to be safe, no clinically meaningful improvements in cognition were recorded. Yet there are reasons to remain optimistic. "Our goal was to change the course of Parkinson's dementia," says neurologist Stephen Pasternak from Western University in Canada. "This early trial offers hope and provides a strong foundation for larger studies." In the team's analysis, some participants carrying a high-risk GBA1 gene for Parkinson's showed improved cognitive performance on ambroxol. With a small sample size and no control group to compare outcomes to, the authors caution these results need to be followed up before drawing any conclusions. That said, high-risk GBA1 gene variants tend to result in lower activity of the enzyme Glucocerebrosidase (GCase), and this, in turn, is linked to more protein clumps in the brain, like Lewy bodies, which are associated with Parkinson's dementia. Recently, studies have found that ambroxol can significantly increase GCase activity. In the current trial, those taking the drug showed 1.5 times the amount of GCase activity. No serious adverse effects were reported by those taking ambroxol, although mild to moderate gastrointestinal issues were common and caused a few participants to drop out of the trial. The findings suggest that some of the more serious symptoms of Parkinson's disease may be managed by ambroxol if taken regularly at high doses. Because ambroxol can easily cross the blood-brain barrier, some scientists suspect the cough medicine can treat neurodegenerative conditions, like Parkinson's, Amyotrophic lateral sclerosis (ALS), Gaucher disease, neuroinflammation, or spinal cord injury. Whether that hypothesis proves to be true requires more clinical research. But the recent phase 2 trial on Parkinson's dementia gives scientists good reason to keep digging. "These findings suggest ambroxol may protect brain function, especially in those genetically at risk," says Pasternak. "It offers a promising new treatment avenue where few currently exist. If a drug like Ambroxol can help, it could offer real hope and improve lives." The study was published in JAMA Neurology. Scientists Finally Uncovered Where Gluten Reactions Start One Major Feature of Aging Might Not Be Universal After All Brain's Memory Center Never Stops Making Neurons, Study Confirms
Yahoo
7 hours ago
- Yahoo
Stanford scientists 'totally surprised' by potential Parkinson's treatment discovery
A recent study from Stanford Medicine that "totally surprised" researchers highlighted what could be a promising approach to slowing Parkinson's disease progression. The research, published in the journal Science Signaling, took a closer look at enzymes — proteins in the body that speed up chemical reactions and are essential for digestion, liver function and other key functions, according to Cleveland Clinic — and their role in Parkinson's. The team found that targeting a certain enzyme helped to restore neuron and cell communication in mice. Music Conductor With Parkinson's Sees Symptoms Improve With Deep Brain Stimulation Lead author Suzanne Pfeffer, PhD, the Emma Pfeiffer Merner Professor in Medical Sciences and a professor of biochemistry at Stanford, told Fox News Digital that the team was "totally surprised that we saw as much improvement as we did." In about 25% of Parkinson's cases, the culprit is some form of genetic mutation. One of the most common mutations creates an overactive enzyme called LRRK2, according to a Stanford press release. Read On The Fox News App When there is too much LRRK2 activity, it changes the structure of the brain cells, disrupting important communication between neurons and cells. This system is crucial to movement, motivation and decision-making, according to the researchers. The goal of the study was to determine whether a specific molecule — the MLi-2 LRRK2 kinase inhibitor — could reverse the effect of overactive enzymes. Parkinson's Patients Who Take 'Magic Mushrooms' See Key Benefits, Study Finds Using mice that had the genetic mutation that causes overactive LRRK2 and also had symptoms consistent with early Parkinson's disease, the scientists tried feeding them the inhibitor for two weeks. There were initially no changes detected in brain structure, signaling or function of the dopamine neurons. However, after three months of eating the inhibitor, mice affected by the overactive enzyme appeared to have restored their neurons to the point where they were virtually the same as those without the genetic mutation, the study found. "Findings from this study suggest that inhibiting the LRRK2 enzyme could stabilize the progression of symptoms if patients can be identified early enough," Pfeffer said in the press release. The study did have some limitations, the researchers acknowledged. "This was in mice, not people, but our current results indicate that similar pathways are important in humans," Pfeffer told Fox News Digital. While the study focused on a specific genetic form of the disease, overactive LRRK2 is also present in other cases, meaning this treatment could help multiple types of Parkinson's patients and possibly those with other neurodegenerative diseases, the reseachers claimed. Looking ahead, the team plans to investigate whether other forms of Parkinson's could benefit. Click Here To Sign Up For Our Health Newsletter Parkinson's — a disease that involves the slow death of dopamine-producing neurons, leading to symptoms like tremors and stiffness — affects nearly one million Americans, according to the Parkinson's Foundation, which has offices in New York and Miami. Experts agree that early intervention is key, as Parkinson's symptoms often appear years after the disease begins. Identifying and treating at-risk individuals sooner could potentially halt or reverse neuron loss. "These findings suggest that it might be possible to improve, not just stabilize, the condition of patients with Parkinson's disease," Pfeffer said. For more Health articles, visit The researcher told Fox News Digital that it's important to encourage patients to undergo genetic testing to learn more about their suitability for clinical trials and future treatments. The study was funded by The Michael J. Fox Foundation for Parkinson's Research, the Aligning Science Across Parkinson's initiative and the United Kingdom Medical Research article source: Stanford scientists 'totally surprised' by potential Parkinson's treatment discovery
Associated Press
10 hours ago
- Associated Press
New Campaign Supports Early-Career Parkinson Researchers
Fuel the Future of Parkinson Science campaign supports early-career Parkinson researchers by providing travel grants to attend the 7th World Parkinson Congress. 'WPC believes every voice matters, especially those who are shaping the future of Parkinson's research.'— Elizabeth Pollard, WPC Executive Director, World Parkinson Coalition NEW YORK, NY, UNITED STATES, July 8, 2025 / / -- The " Fuel the Future of Parkinson Science " campaign kicked off in honor of Research Appreciation Day on July 5. This campaign, being run by the World Parkinson Coalition®, supports early-career researchers in the Parkinson's field by providing travel grants to attend the 7th World Parkinson Congress (WPC 2026) in Phoenix, AZ, in May 2026. Many talented young scientists have lost access to critical funding due to budget cuts, changing institutional priorities, and other challenges, putting their participation—and their contributions—at risk. WPC 2026 will be a global convergence of scientists, clinicians, people living with Parkinson's, and advocates. We believe every voice matters, especially those who are shaping the future of Parkinson's research. A financial gift to this campaign will help remove barriers for the brightest emerging minds to share their work, build global connections, and stay actively engaged in the Parkinson's community – moving us closer to a cure. This campaign is being kicked off by WPC board member, Dr. Jeffrey Kordower. Dr. Kordower is the founding director of the ASU Banner Neurodegenerative Disease Research Center (NDRC) at the Biodesign Institute. One of NDRC's core missions is to support the next generation of scientists and so, towards that end, the NDRC will MATCH donations to this fund UP TO $15,000 starting immediately. Meeting the full match will allow the WPC to raise $30,000 for travel grants for early career investigators to attend the WPC 2026. 'I attended the first World Parkinson Congress in 2006 and was so deeply moved and impacted by the experience of the whole community coming together to learn and share, that I have championed the WPC ever since, and I always ensure my whole team attends whenever and wherever possible,' Dr. Jeffrey Kordower With your support today, the WPC can raise $30,000 for early career researchers to attend the upcoming WPC 2026. This campaign is supported by a growing and powerful coalition of committed researchers and community members who want to ensure early career researchers have a place at the table. View video messages from others who are supporting this campaign here. 'WPC believes every voice matters, especially those who are shaping the future of Parkinson's research. Each gift to this new campaign helps remove financial barriers and ensures that future researchers can be with us in Phoenix next year sharing their research, learning from people with Parkinson's and moving us closer to a cure,' Elizabeth Pollard, WPC Executive Director, World Parkinson Coalition. This campaign concludes on November 10, 2025, on World Science Day for Peace & Development Julie Winn World Parkinson Coalition +1 802-578-1704 email us here Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
